Results 181 to 190 of about 57,565 (259)

ASO Author Reflections: Hormonal Status May Impact Outcomes in Peritoneal Mesothelioma After CRS/HIPEC. [PDF]

Ann Surg Oncol
Cummins KC, Ruff SM.
europepmc   +1 more source

A case of delayed recurrence of pleural mesothelioma with intradural invasion. [PDF]

Surg Neurol Int
Sato H, Omichi R, Nigami Y, Shimokawa N.
europepmc   +1 more source

Persistence burden and poor survival of pleural mesothelioma in central Italy, 2013-2022: a population-based study thirty years after asbestos ban. [PDF]

BMC Public Health
Iommi M, Bonifazi M, Sarti D, Mei F, Franchi M, Rossi M, Pompili M, Prospero E, Carle F, Gesuita R, Skrami E.   +10 more
europepmc   +1 more source

Exercise Boosts the Immune System and Enhances Immunotherapy Responses in Pancreatic Cancer and Mesothelioma. [PDF]

Biomolecules
Hapuarachi B, Danson S, Wadsley J, Brown H, Southam P, Muthana M.   +5 more
europepmc   +1 more source

Inactivation of <i>BAP1</i> and the Hippo Pathway Characterizes the Genomic Alterations of Peritoneal Mesothelioma. [PDF]

Life (Basel)
Samuels M, Williams M, Hasan A, Rafie S, Saglimbeni GS, Hsia B, Nair S, Aeilias S, Tauseef A.   +8 more
europepmc   +1 more source

Nicotinamide mononucleotide enhances anti-tumor effect by resetting macrophages toward the inflammatory M1-like phenotype. [PDF]

Mol Ther Oncol
Xu H, Wan MCT, Wong CCC, Qin S, Wen Y, Wang J, Chen Z.   +6 more
europepmc   +1 more source

Disease burden of asbestos-related diseases in China (1990-2023) based on GBD estimates: A call for stronger labor protection laws. [PDF]

PLoS One
An D, Shi Z, Zhang C, Song S, Wang L, Li H.   +5 more
europepmc   +1 more source

Correction to 'Cul4A is an oncogene in malignant pleural mesothelioma'. [PDF]

J Cell Mol Med
europepmc   +1 more source

Hormonal Status May Contribute to Sex-Based Survival Differences in Epithelioid Peritoneal Mesothelioma. [PDF]

Ann Surg Oncol
Cummins KC, Sears O, Bitar ER, Shen C, Tsung A, Ruff SM.   +5 more
europepmc   +1 more source

Molecular profiling and personalized medicine within EURACAN in the SPECTA Arcagen study in comparison to the France Genomic Medicine 2025 Plan in the AURAGEN platform in peritoneal mesotheliomas. [PDF]

Transl Oncol
Momenkhan S, Morfouace M, Kepenekian V, Glehen O, Villeneuve L, Oliveira J, Tejpar S, Isaac S, Fontaine J, Blay JY, Péron J, Benzerdjeb N.   +11 more
europepmc   +1 more source